Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.
Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.
复制标题
冠状病毒疾病（COVID-19）相关的粘膜细胞增多症（CAM）：病例报告和文献综述。
DOI：
10.1007/s11046-021-00528-2
复制
发表时间：
2021-05
期刊：
影响因子：
5.5
通讯作者：
Agarwal R
中科院分区：
文献类型：
--
作者：
Garg D;Muthu V;Sehgal IS;Ramachandran R;Kaur H;Bhalla A;Puri GD;Chakrabarti A;Agarwal R
严重冠状病毒病（COVID-19）目前使用全身性糖皮质激素进行管理。真菌感染是这些患者的关注点。虽然COVID-19相关的肺曲霉病越来越多地被认识到，但毛霉菌病很少见。我们描述了一例55岁男性糖尿病、终末期肾病和COVID-19疑似肺毛霉菌病的病例。指示病例在因严重COVID-19入院后21天被诊断为肺毛霉菌病。他接受了5 g脂质体阿替霉素B，并在54天后出院。我们还对文献进行了系统回顾，并确定了另外7例COVID-19相关毛霉菌病（CAM）病例。在我们回顾的8例病例中，糖尿病是最常见的危险因素。3名受试者除糖皮质激素外没有COVID-19的风险因素。毛霉菌病通常在住院后10-14天发生。除索引病例外，所有病例均死亡。在两名受试者中，CAM是在死后诊断的。毛霉菌病是一种罕见但严重的感染，使严重的COVID-19病程复杂化。患有糖尿病和多种风险因素的受试者发生毛霉菌病的风险可能更高。同时糖皮质激素治疗可能增加毛霉菌病的风险。需要高度怀疑和积极的管理来改善结果。
Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids. Opportunistic fungal infections are of concern in such patients. While COVID-19 associated pulmonary aspergillosis is increasingly recognized, mucormycosis is rare. We describe a case of probable pulmonary mucormycosis in a 55-year-old man with diabetes, end-stage kidney disease, and COVID-19. The index case was diagnosed with pulmonary mucormycosis 21 days following admission for severe COVID-19. He received 5 g of liposomal amphotericin B and was discharged after 54 days from the hospital. We also performed a systematic review of the literature and identified seven additional cases of COVID-19 associated mucormycosis (CAM). Of the eight cases included in our review, diabetes mellitus was the most common risk factor. Three subjects had no risk factor other than glucocorticoids for COVID-19. Mucormycosis usually developed 10–14 days after hospitalization. All except the index case died. In two subjects, CAM was diagnosed postmortem. Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis. Concurrent glucocorticoid therapy probably heightens the risk of mucormycosis. A high index of suspicion and aggressive management is required to improve outcomes.
登录
查看更多内容
影响因子：
14.2
作者：
Patel, A.;Kaur, H.;Chakrabarti, A.
通讯作者：
Chakrabarti, A.
影响因子：
3.6
作者：
Werthman-Ehrenreich, Amanda
通讯作者：
Werthman-Ehrenreich, Amanda
影响因子：
--
作者：
Placik DA;Taylor WL;Wnuk NM
通讯作者：
Wnuk NM
DOI：
10.1016/s1473-3099(20)30847-1
发表时间：
2021-06
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Koehler P;Bassetti M;Chakrabarti A;Chen SCA;Colombo AL;Hoenigl M;Klimko N;Lass-Flörl C;Oladele RO;Vinh DC;Zhu LP;Böll B;Brüggemann R;Gangneux JP;Perfect JR;Patterson TF;Persigehl T;Meis JF;Ostrosky-Zeichner L;White PL;Verweij PE;Cornely OA;European Confederation of Medical Mycology;International Society for Human Animal Mycology;Asia Fungal Working Group;INFOCUS LATAM/ISHAM Working Group;ISHAM Pan Africa Mycology Working Group;European Society for Clinical Microbiology;Infectious Diseases Fungal Infection Study Group;ESCMID Study Group for Infections in Critically Ill Patients;Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy;Medical Mycology Society of Nigeria;Medical Mycology Society of China Medicine Education Association;Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology;Association of Medical Microbiology;Infectious Disease Canada
通讯作者：
Infectious Disease Canada
重症患者的IL-6抑制作用与继发感染增加有关。
影响因子：
3.9
作者：
Kimmig LM;Wu D;Gold M;Pettit NN;Pitrak D;Mueller J;Husain AN;Mutlu EA;Mutlu GM
通讯作者：
Mutlu GM